Amgen Introduces Direct-to-Patient Access for Repatha in US
MT Newswires Live
Yesterday
Amgen (AMGN) said Monday it launched AmgenNow, a direct-to-patient program in the US starting with its cholesterol drug Repatha, or evolucumab.
The company said eligible patients can buy Repatha through the program for $239 per month, about 60% lower than the drug's current list price. The program is open to patients who are uninsured, in high-deductible health plans, or prefer to pay out of pocket, according to Amgen.
The program will be available to all Repatha patients, including those on Medicare and Medicaid, and will not require step therapy or prior authorization, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.